HeartBeam Inc. Receives FDA Clearance for Innovative Cable-Free ECG System
June 20th, 2025 2:30 PM
By: Newsworthy Staff
HeartBeam Inc. has achieved FDA 510(k) clearance for its pioneering, credit card-sized, cable-free ECG system, enhancing remote arrhythmia detection and cardiac care accessibility.
HeartBeam Inc. (NASDAQ: BEAT) has reached a significant milestone with the FDA 510(k) clearance of its flagship ECG system, a compact, cable-free device designed for arrhythmia detection. This innovation allows patients to record a 30-second ECG using an app-guided system, which is then uploaded to the cloud for physician review, integrating medical history for comprehensive evaluation.
The company plans to initiate an Early Access Program to involve early adopters and healthcare providers, paving the way for broader commercialization. This clearance not only facilitates immediate advancements in cardiac care but also lays the groundwork for future developments, including 12-lead ECG synthesis and AI-based arrhythmia detection, aiming to provide continuous, predictive cardiac insights outside traditional clinical settings.
HeartBeam's vision is to transform cardiac care by enabling actionable heart intelligence anywhere, potentially redefining cardiac health management. With 13 U.S. and 4 international patents, the company is at the forefront of medical technology innovation. For more details, visit https://ibn.fm/go8CI.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
